Early medical abortion in India: three studies and their implications for abortion services.
Although legal in India, abortion is frequently performed under unsafe or undesirable conditions. Moreover, the advancements required to make surgical abortion safe in India appear insurmountable in the near future. Because it requires a less extensive infrastructure than surgical abortion, medical abortion offers great potential for improving abortion access and safety now. To examine the feasibility of introducing medical abortion and to assess its potential as an alternative to surgical abortion, we conducted three separate studies on the use of 600 mg mifepristone and 400 micrograms oral misoprostol for medical abortion. Study 1 focused on the safety, efficacy, and feasibility of the standard French, three-visit protocol and was conducted in urban research centers in China, Cuba, and India. Study 2 liberalized the protocol to collect information from women using the method under more "real life" conditions in urban family planning clinics in India. Lastly, study 3 extended the trial to rural Indian villages to examine feasibility in settings typical of where the majority of the population resides. In all three settings in India mifepristone-misoprostol proved to be not only feasible, but safe and acceptable as well. With some changes to current protocols, medical abortion could now be safely phased into the existing health care infrastructure in India. Yet, medical abortion will bring its own set of service delivery challenges to address.
Coyaji
K
K
Department of Obstetrics and Gynecology, KEM Hospital, Rasta Peth, Pune, India.
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D005240:Feasibility Studies; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D007194:India; D015735:Mifepristone / Q000008:administration & dosage* / Q000627:therapeutic use; D016595:Misoprostol / Q000008:administration & dosage* / Q000627:therapeutic use; D017060:Patient Satisfaction; D011247:Pregnancy; D012424:Rural Population; D014505:Urban Population
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone